PCI Biotech Holding ASA is a leading biotechnology company that upholds strong values and a well-defined corporate philosophy. The company envisions transforming patient care through innovative therapeutic solutions. PCI Biotech Holding ASA focuses on developing and commercializing its proprietary drug delivery technologies for the treatment of serious diseases, with a particular emphasis on cancer. With a commitment to scientific excellence, ethical conduct, and patient-centric approach, the company aims to create value for patients, healthcare providers, and shareholders alike. Embracing continuous innovation and collaboration, PCI Biotech Holding ASA aims to make a positive impact on healthcare outcomes worldwide.

PCI Biotech Holding ASA is primarily present in Norway.

PCI Biotech Holding ASA has achieved several significant milestones. The company successfully completed a Phase I clinical trial for its lead product, Amphinex, which showed promising results in treating bile duct cancer. Additionally, PCI Biotech Holding ASA secured a collaboration agreement with a major pharmaceutical company to explore the potential of Amphinex in combination with their immunotherapy drug. The company also received Orphan Drug Designation in Europe for the treatment of bile duct cancer using Amphinex. These achievements demonstrate PCI Biotech Holding ASA's dedication to advancing cancer treatments and highlight the potential of its innovative technology.

PCI Biotech Holding ASA is a Norwegian biopharmaceutical company established in 2000. With a focus on developing innovative cancer treatments, PCI Biotech Holding ASA has built a strong history and background in the field. The company specializes in developing photosensitizers, light sources, and drug delivery technologies for cancer therapy. PCI Biotech Holding ASA is known for its expertise in photochemical internalization (PCI), a technology that enhances the effect of drugs by releasing them inside cells. This innovative approach holds great potential for improving cancer treatment outcomes. Over the years, PCI Biotech Holding ASA has garnered recognition and formed strong partnerships within the healthcare industry, solidifying its position as a leader in the field of cancer therapeutics.

The main competitors of PCI Biotech Holding ASA in the market are other biotech companies and pharmaceutical companies that operate in the same field of research and development. Some notable competitors include AstraZeneca, Novartis, Pfizer, and Gilead Sciences. These companies, like PCI Biotech Holding ASA, are engaged in the development of innovative therapies, drugs, and treatments aimed at addressing various diseases and conditions. PCI Biotech Holding ASA strives to differentiate itself through its unique approaches and technology platforms to gain a competitive edge in the market.

PCI Biotech Holding ASA is primarily active in the pharmaceutical and biotechnology industries.

The business model of PCI Biotech Holding ASA is focused on the development and commercialization of innovative therapies targeting cancer through its proprietary platform technology, known as Photochemical Internalization (PCI). PCI Biotech aims to improve the efficacy of existing treatments by enhancing the delivery of drugs to cancer cells, thus increasing the potential for successful outcomes. By leveraging its expertise in drug delivery and partnering with pharmaceutical companies, PCI Biotech aims to bring novel and effective therapeutics to market, addressing unmet medical needs and ultimately benefiting patients worldwide.

PCI Biotech Holding A KGV ir -0,63.

PCI Biotech Holding A KUV ir 7,20.

AlleAktien kvalitātes vērtējums PCI Biotech Holding A ir 3/10.

gaidāmā PCI Biotech Holding A apgrozījums ir 7,27 milj. NOK.

gaidāmā PCI Biotech Holding A peļņa ir -83,08 milj. NOK.

PCI Biotech Holding ASA is a Norwegian biotechnology company specializing in the development of drugs for the treatment of severe diseases. The company was founded in 2000 and specializes in the development of drugs based on phototherapy. The company operates in two main business areas: PCI (Photochemical Internal Therapy) and fimaNAc (nanoparticle-based mRNA delivery). PCI (Photochemical Internal Therapy) is a proprietary technology platform for targeted release of drugs into cells. The PCI technology is based on a combination of light-sensitive drugs that target specific cells or tissues, and targeted light that triggers the release of the drugs. The PCI technology has the potential to increase the efficacy of existing drugs and create new therapies and treatment options for a variety of diseases. In the field of fimaNAc (nanoparticle-based mRNA delivery), PCI Biotech has developed a technology platform focusing on the use of nanoparticles for targeted delivery of mRNA drugs. The fimaNAc technology combines the advantages of lipid and polymer nanoparticles, allowing the transport of mRNA molecules into cells. fimaNAc is a revolutionary technology that has the potential to increase the efficacy of mRNA-based drugs and create new therapies for a variety of diseases. PCI Biotech has successfully conducted clinical trials with promising results in both business areas. The company has entered into several partnerships with leading biotechnology and pharmaceutical companies to utilize its technology platforms and further develop its drug candidates. In addition, the company works closely with academic and clinical partners to identify and develop new therapy options for patients. PCI Biotech's key product is Amphinex, which is currently under investigation in advanced clinical trials for the treatment of pancreatic cancer. Amphinex is used in combination with the chemotherapy drug Gemcitabine and has the potential to significantly improve the response to chemotherapy. Another promising product from PCI Biotech is a collaborative development alliance with AstraZeneca in the field of fimaNAc technology for the treatment of cancer. The alliance aims to utilize PCI Biotech's fimaNAc technology for efficient delivery of mRNA drugs that influence the production of proteins crucial for the growth of cancer cells. Overall, PCI Biotech has developed a promising technology platform that has the potential to revolutionize the treatment of serious diseases such as cancer. The company has leveraged collaborations with leading biotechnology and pharmaceutical companies to utilize its technology platforms and further develop its drug candidates. With a promising product pipeline and strong financial position, PCI Biotech is positioning itself as a leading company in the biotechnology industry.

PCI Biotech Holding A izmaksā dividendes 0 NOK, kas tiek izmaksātas reizes gadā.

Dividendes pašlaik nevar aprēķināt PCI Biotech Holding A vai uzņēmums nedod dividendes.

PCI Biotech Holding A ISIN ir NO0010405640.

PCI Biotech Holding A WKN ir A0Q2FS.

PCI Biotech Holding A simbols ir PCIB.OL.

Pēdējo 12 mēnešu laikā PCI Biotech Holding A maksāja dividendes apmērā. Tas atbilst aptuveni dividendes ražībai. Nākamajos 12 mēnešos PCI Biotech Holding A plāno maksāt dividendes 0 NOK apmērā.

PCI Biotech Holding A pašreizējā dividendu rentabilitāte ir .

PCI Biotech Holding A maksā dividendes ceturksnī. Tās tiek izmaksātas mēnešos .

PCI Biotech Holding A pēdējo 0 gadu laikā katru gadu izmaksāja dividendes.

Nākamajiem 12 mēnešiem tiek prognozētas dividendes apmērā 0 NOK. Tas atbilst dividendes ražībai 0 %.

PCI Biotech Holding A tiek piešķirts nozarei "Veselība".

Lai saņemtu pēdējo dividendu PCI Biotech Holding A apmērā 0 NOK, kas tika izmaksāta 22.11.2024., tev akcija bija jāpatur depozītā līdz Ekss dienai, kas bija 22.11.2024..

Pēdējās dividendes izmaksa notika 22.11.2024..

Gadā 2023, PCI Biotech Holding A izmaksāja 0 NOK dividendes.

PCI Biotech Holding A dividendes tiek izmaksātas NOK.